ReviewPharmacoEconomics2019

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Nasuh C Büyükkaramikli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.